SUSMED's development pipeline of therapeutic and diagnostic apps had expanded to 11 programs as of 7 August 2026. The company has disclosed the preparation and progress of clinical and exploratory trials aimed at treating or preventing various conditions.
SUSMED disclosed that its development pipeline of therapeutic and diagnostic apps, excluding the app for insomnia disorder, comprised 11 programs as of 7 August 2026. The SMD401 exercise therapy app for breast cancer patients has completed its exploratory trial and is being prepared for the next trial. SMD402 is a medical device for ACP for patients with advanced or recurrent cancer, and a company-sponsored clinical trial is under way, with results also presented at ASCO.
The SMD201 rehabilitation app for chronic kidney disease has completed its exploratory trial and is being prepared for the next trial. SUSMED is developing SMD102 for persistent depressive disorder and has published a paper. Development of SMD202 is under way in preparation for the start of an exploratory trial for opioid-induced constipation.
Promising results were reported from a study at Tokai University Hospital for the tinnitus treatment app KRP-DT123/SMD403, and a confirmatory trial was started as a clinical trial in May 2026. SMD105 is an ACT app for PMPS and is undergoing an exploratory trial. SMD106 began a specified clinical trial for PMS/PMDD and, following confirmation of its efficacy, is being prepared for the next trial.
A clinical trial of SMD107 for PPPD ended at Niigata University, and a report that the treatment effect was maintained for a certain period was presented at the Oto-Rhino-Laryngological Society of Japan. For SMD103, a patent has been granted for an algorithm and device targeting perinatal depression, and preparations are under way to begin an exploratory trial. Preparations are also under way to begin an exploratory trial of SMD104 for ADHD diagnosis through eye-tracking analysis.